Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07224178 · ClinicalTrials.gov registry record

Left Atrial Strain and Cryptogenic Stroke

A clinical trial of Hemorrhagic Stroke and Ischemic Stroke, Cryptogenic, sponsored by University of Pittsburgh.

Recruiting
Registry status
900
Enrollment target
1
Study location

NCT07224178: Recruiting study of Hemorrhagic Stroke and Ischemic Stroke, Cryptogenic, sponsored by University of Pittsburgh.

NCT07224178 is a study of Hemorrhagic Stroke and Ischemic Stroke, Cryptogenic that is actively recruiting participants, run by University of Pittsburgh. The registered enrollment target is 900 participants, below the 10,248-participant average among 6 other Hemorrhagic Stroke trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07224178, a study of Hemorrhagic Stroke and Ischemic Stroke, Cryptogenic, is actively recruiting participants, sponsored by University of Pittsburgh.

RECRUITING
Registry status
900 participants
Enrollment target
1
Study location

Study Summary

Cryptogenic stroke is a type of stroke in which the cause of the blood clot cannot be identified, leaving many patients without a clear treatment plan and at high risk for another stroke. Current medical guidelines recommend blood-thinning medication (anticoagulation) only when atrial fibrillation (AF) -an irregular heart rhythm- can be documented. However, AF may occur silently and remain undetected. Long term implantable (placed invasively under the skin) devices may be needed to capture these episodes. AF is known to develop from disease of the left atrium, the upper chamber of the heart that receives blood from the lungs. When the left atrium does not contract normally, blood flow may slow down, increasing the risk of clot formation. Nowadays, the left atrial (LA) function can be quantified precisely using a noninvasive ultrasound technique called strain imaging. This study aims to determine whether reduced LA function is associated with cryptogenic stroke and its recurrence even when AF is not observed. If such an association is confirmed, LA strain could serve as a new biomarker to identify patients at risk, earlier than the development of overt AF, enhance preventive measures to reduce recurrent strokes. Because echocardiographic strain imaging is safe, cost-effective, and widely available, it may become an important tool for improving care in this high-risk population.

Primary Outcome

Quantitative left atrial (LA) strain (% deformation), measured by speckle-tracking echocardiography from transthoracic echocardiograms obtained during stroke workup, will be compared with the rate of cryptogenic stroke.

Study Locations (1)

Pennsylvania

  • UPMC Presbyterian - Pittsburgh

Trial Details

FieldValue
Enrollment Target 900 participants
Start Date 2025-12-17
Est. Completion 2027-12-31
University of Pittsburgh

1,238 total trials

What NCT07224178 shows while recruiting

NCT07224178 is an observational study that tracks outcomes without assigning an intervention. The registered 900 participants enrollment target is mid-sized for trials with a published cap, below the 10,248-participant average among 6 other Hemorrhagic Stroke trials with a reported enrollment target (91% lower).

The record links to 5 conditions, with Hemorrhagic Stroke appearing as the primary indexed condition, and to 0 interventions.

NCT07224178 reports a single indexed study location in Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT07224178 about?

NCT07224178 is a clinical study titled "Left Atrial Strain and Cryptogenic Stroke". Cryptogenic stroke is a type of stroke in which the cause of the blood clot cannot be identified, leaving many patients without a clear treatment plan and at high risk for another stroke. Current medical guidelines recommend blood-thinning medication (anticoagulation) only when atrial fibrillation (...

What is the current status of trial NCT07224178?

This trial is currently recruiting. The enrollment target is 900 participants. The study started on 2025-12-17. Estimated completion is 2027-12-31.

What conditions does trial NCT07224178 study?

This clinical trial studies the following conditions: Hemorrhagic Stroke, Ischemic Stroke, Cryptogenic, Ischemic Stroke, Embolic, Embolic Stroke of Undetermined Source, Recurrent Ischemic Stroke.

Who is sponsoring clinical trial NCT07224178?

This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07224178 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hemorrhagic Stroke

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02352116 · 900 participants · NA

    Evaluation of Post-PACU Pain Management in Pediatric Surgery

  • NCT02414347 · 900 participants

    F 18 T807 Tau PET Imaging of Alzheimer's Disease

  • NCT02670408 · 900 participants

    Diagnostic and Therapeutic Applications of Microarrays in Heart Transplantation

  • NCT02960022 · 900 participants · Phase 2

    A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07224178, the US trial registry maintained by the National Library of Medicine. NCT07224178 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.